ALKS - Alkermes plc

Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced the presentation of accepted research at key scientific conferences this spring related to its psychiatry products—LYBALVI® (olanzapine and samidorphan) and ARISTADA® (aripiprazole lauroxil)—and its ongoing involvement in sleep medicine. The data presented reflect Alkermes' ongoing commitment to contributing to the advancement of patient care and expanding the body of evidence in neuroscience. The meetings included: The Psych.

May 21, 2026 03:00 AM • businesswire.com

Alkermes Gains Momentum After Sleep Disorder Trial Clears Key Hurdles

Alkermes Inc. plc (NASDAQ:ALKS) stock is trading higher on Tuesday following the announcement of positive topline results from the REVITALYZ phase 3 study evaluating LUMRYZ extended-release oral suspension for excessive daytime sleepiness associated with idiopathic hypersomnia.

May 12, 2026 10:27 AM • benzinga.com

Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced positive topline results from the REVITALYZ℠ double-blind, placebo-controlled, randomized withdrawal, multicenter phase 3 study evaluating the investigational use of LUMRYZ® (sodium oxybate) extended-release oral suspension in adults with idiopathic hypersomnia (IH). LUMRYZ met the study's primary endpoint, demonstrating statistically significant improvements in excessive daytime sleepiness compared to placebo as measured by t.

May 12, 2026 03:00 AM • businesswire.com

Alkermes Analysts Increase Their Forecasts Following Strong Q1 Results

Alkermes (NASDAQ:ALKS) reported upbeat results for the first quarter on Tuesday.

May 06, 2026 09:54 AM • benzinga.com

Alkermes' Q1 Earnings & Revenues Beat Estimates, Stock Rises

ALKS beats Q1 estimates as strong proprietary drug sales lift revenues by 28%, sending shares higher, while Lumryz adds a fresh growth driver.

May 06, 2026 09:10 AM • zacks.com

Alkermes: A Sleep Medicine Platform Hidden Inside A Mature CNS Company

Alkermes is transitioning into an integrated neuroscience and sleep medicine company, highlighted by the Avadel acquisition and LUMRYZ integration. Q1 2026 results show proprietary product sales rising to $338.1M, with LUMRYZ contributing $39.5M post-acquisition; adjusted EBITDA improved to $80.3M. Management projects 2026 revenues of $1.73–$1.84B, with four commercial products each targeting over $300M in annual net sales.

May 06, 2026 03:30 AM • seekingalpha.com

Alkermes plc (ALKS) Q1 2026 Earnings Call Transcript

Alkermes plc (ALKS) Q1 2026 Earnings Call Transcript

May 05, 2026 11:41 AM • seekingalpha.com

Alkermes (ALKS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for Alkermes (ALKS) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

May 05, 2026 06:36 AM • zacks.com

Alkermes (ALKS) Reports Q1 Loss, Beats Revenue Estimates

Alkermes (ALKS) came out with a quarterly loss of $0.4 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to earnings of $0.13 per share a year ago.

May 05, 2026 05:26 AM • zacks.com

Alkermes plc Reports First Quarter 2026 Financial Results

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter ended March 31, 2026 and financial expectations for full year 2026. To view the detailed first quarter 2026 earnings press release and presentation, please visit the company's investor relations website at https://investor.alkermes.com. Alkermes will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) today to discuss these financial results and expectations and prov.

May 05, 2026 03:00 AM • businesswire.com

Bristol Myers Squibb (BMY) Tops Q1 Earnings and Revenue Estimates

Bristol Myers Squibb (BMY) came out with quarterly earnings of $1.58 per share, beating the Zacks Consensus Estimate of $1.44 per share. This compares to earnings of $1.8 per share a year ago.

Apr 30, 2026 05:30 AM • zacks.com

Earnings Preview: Alkermes (ALKS) Q1 Earnings Expected to Decline

Alkermes (ALKS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Apr 28, 2026 07:09 AM • zacks.com

Wall Street Analysts Believe Alkermes (ALKS) Could Rally 29.14%: Here's is How to Trade

The consensus price target hints at a 29.1% upside potential for Alkermes (ALKS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Apr 28, 2026 06:56 AM • zacks.com

Abacus FCF Advisors LLC Makes New Investment in Alkermes plc $ALKS

Abacus FCF Advisors LLC bought a new position in shares of Alkermes plc (NASDAQ: ALKS) during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 219,495 shares of the company's stock, valued at approximately $6,141,000. Abacus FCF Advisors LLC owned 0.13%

Apr 25, 2026 11:14 PM • defenseworld.net

Alkermes to Report First Quarter Financial Results on May 5, 2026

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Tuesday, May 5, 2026 to discuss the company's first quarter financial results. The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. A replay of the webcast wi.

Apr 21, 2026 12:05 PM • businesswire.com

Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced plans to present new data from the Vibrance-1 phase 2 study evaluating alixorexton in patients with narcolepsy type 1 (NT1) at the American Academy of Neurology (AAN) 2026 Annual Meeting, taking place April 18-22, 2026 in Chicago. Alixorexton is a novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development for the treatment of NT1, narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH). Vibrance-1,.

Apr 16, 2026 03:00 AM • businesswire.com

Findings From Long-Term Analysis of the Effects of LYBALVI® (olanzapine and samidorphan) on Negative Symptoms of Schizophrenia Published in The Journal of Clinical Psychiatry

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced the publication of a 56-week post hoc analysis of the effects of LYBALVI® (olanzapine and samidorphan) on negative symptoms in adults living with schizophrenia in the peer-reviewed publication The Journal of Clinical Psychiatry. The analysis—titled “The Efficacy of Olanzapine/Samidorphan on Negative Symptoms: A Post Hoc Analysis of 56-Week Treatment in Patients With Schizophrenia”—found that treatment with LYBALVI was associat.

Apr 14, 2026 03:00 AM • businesswire.com

Top 2 Health Care Stocks That May Implode In April

As of April 1, 2026, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Apr 01, 2026 04:34 AM • benzinga.com

These 5 Biotechs Could Be the Next Big GLP-1 Acquisition Target

The GLP-1 revolution has reshaped biopharma M&A strategy. With Novo Nordisk and Eli Lilly generating tens of billions in annual obesity drug revenue, large-cap acquirers are scouring the biotech landscape for the next transformative asset.

Apr 01, 2026 03:35 AM • 247wallst.com

Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced the initiation of the Brilliance Studies, a phase 3 program evaluating the safety and efficacy of alixorexton compared to placebo in adults with narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2). Alixorexton is the company's novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development for the treatment of NT1, NT2 and idiopathic hypersomnia (IH). The Brilliance Studies program consists of three 12-.

Apr 01, 2026 03:00 AM • businesswire.com

Alkermes price target raised to $50 from $45 at Needham

$50.00 (was $35.62)

Needham

May 06, 2026 09:45 AM • TheFly

Alkermes (ALKS) PT Lowered to $43 at H.C. Wainwright

$43.00 (was $31.04)

Douglas Tsao · H.C. Wainwright

Feb 26, 2026 06:39 AM • StreetInsider

Alkermes initiated with an Outperform at Wolfe Research

$45.00 (was $32.19)

Wolfe Research

Feb 23, 2026 04:09 PM • TheFly

Jefferies on Alkermes (ALKS) Earnings: 'Solid Q3 + FY guide raise'

$56.00 (was $30.75)

Akash Tewari · Jefferies

Oct 28, 2025 01:16 PM • StreetInsider

Alkermes price target raised to $45 from $40 at Mizuho

$45.00 (was $29.76)

Mizuho Securities

Oct 27, 2025 07:49 AM • TheFly

Alkermes price target raised to $45 from $38 at Piper Sandler

$45.00 (was $31.09)

David Amsellem · Piper Sandler

Oct 23, 2025 06:29 AM • TheFly

Alkermes price target raised to $47 from $45 at RBC Capital

$47.00 (was $31.09)

RBC Capital

Oct 22, 2025 02:48 PM • TheFly

Alkermes upgraded to Outperform from Sector Perform at RBC Capital

$44.00 (was $28.14)

Alkermes to Outperform · RBC Capital

Sep 26, 2025 05:22 AM • TheFly

Alkermes price target lowered to $43 from $45 at Needham

$43.00 (was $27.85)

Needham

Sep 09, 2025 07:20 AM • TheFly

Questions remain after Alkermes narcolepsy data, says H.C. Wainwright

$46.00 (was $27.77)

Douglas Tsao · H.C. Wainwright

Sep 09, 2025 06:16 AM • TheFly

Alkermes initiated with an Overweight at Wells Fargo

$44.00 (was $29.40)

Wells Fargo

Sep 02, 2025 04:40 PM • TheFly

Alkermes upgraded to Buy from Neutral at UBS

$42.00 (was $29.77)

Ashwani Verma · UBS

Jun 17, 2025 04:25 AM • TheFly

Piper Sandler Reiterates Overweight Rating on Alkermes (ALKS)

$37.00 (was $31.25)

David Amsellem · Piper Sandler

Dec 05, 2024 07:30 AM • StreetInsider

Alkermes (ALKS) PT Raised to $40 at Mizuho

$40.00 (was $26.07)

Vamil Divan · Mizuho Securities

Nov 13, 2024 06:39 AM • StreetInsider

Stifel Upgrades Alkermes (ALKS) to Buy

$36.00 (was $26.59)

Paul Matteis · Stifel Nicolaus

Nov 04, 2024 04:23 PM • StreetInsider

Alkermes (ALKS) PT Lowered to $25 at Stifel

$25.00 (was $26.85)

Paul Matteis · Stifel Nicolaus

Oct 24, 2024 06:56 AM • StreetInsider

H.C. Wainwright Reiterates Neutral Rating on Alkermes (ALKS)

$37.00 (was $28.91)

Douglas Tsao · H.C. Wainwright

Oct 14, 2024 02:58 AM • StreetInsider

Alkermes (ALKS) PT Raised to $50 at Jefferies

$50.00 (was $13.37)

Akash Tewari · Jefferies

Apr 10, 2024 03:44 AM • StreetInsider

Mizuho on Alkermes (ALKS): 'We maintain our Buy rating, believing that ALKS 2680 is underappreciated'

$35.00 (was $26.73)

Vamil Divan · Mizuho Securities

Apr 09, 2024 08:45 AM • StreetInsider

Alkermes price target raised to $50 at Jefferies after 'excellent' NT2 data

$25.00 (was $26.95)

Akash Tewari · Jefferies

Apr 09, 2024 08:04 AM • TheFly